Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases
Pediatric Blood & Cancer · 2026-07 · 73 (7)
DOI: 10.1002/1545-5017.70325 ↗Kurz gefasst
Scoping Review in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 16.04.2026. Verfasst von Will Swansson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sirolimus, Arteriovenous Malformations. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear. This scoping review investigates the current evidence base around the use of sirolimus for AVMs. Twenty‐one reports encompassing a total of 60 patients with AVMs treated with systemic sirolimus were included. Sirolimus was predominantly used as an adjunct or salvage therapy. Response was variable overall; however, there was a more consistent benefit in patients with PTEN hamartoma syndrome (PHTS)‐associated AVMs, where PI3K/AKT/mTOR pathway dysregulation provides a molecular basis for sirolimus efficacy. Standardised outcome reporting, routine molecular profiling, and larger multicentre collaboration are needed to better define the role of sirolimus for AVMs, particularly as part of multimodal care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Genetic Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Respiratory Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Dermatology, Western Health, Melbourne, Victoria, Australia.
- Department of Dermatology, The Royal Children's Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Will Swansson
Zitieren
APA
Swansson, W., Winship, I., Hammerschlag, G., & Scardamaglia, L. (2026). Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases. Pediatric Blood & Cancer, 73(7). https://doi.org/10.1002/1545-5017.70325
Vancouver
Swansson W, Winship I, Hammerschlag G, Scardamaglia L. Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases. Pediatric Blood & Cancer. 2026;73(7). doi:10.1002/1545-5017.70325
BibTeX
@article{Swansson2026,
author = {Swansson, Will and Winship, Ingrid and Hammerschlag, Gary and Scardamaglia, Laura},
title = {Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {7},
doi = {10.1002/1545-5017.70325}
}
EUVIMED